Back to top
more

Global Blood Therapeutics, Inc. (GBT)

(Delayed Data from NSDQ)

$55.18 USD

55.18
646,468

+1.34 (2.49%)

Updated May 3, 2019 04:00 PM ET

After-Market: $55.12 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[GBT]

Reports for Purchase

Showing records 221 - 240 ( 340 total )

Industry: Medical - Biomedical and Genetics

Record: 221

05/20/2019

Industry Report

Pages: 4

IMR-687, Poised to Challenge HU While Simultaneously Making a Run at Selectins

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 222

05/17/2019

Industry Report

Pages: 6

HEALTHCARE - EHA Abstract Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 223

05/17/2019

Daily Note

Pages: 10

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 224

05/16/2019

Company Report

Pages: 5

EHA Preview: Top-line Voxelotor Phase 3 HOPE Data at EHA on June 14

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 225

05/13/2019

Company Report

Pages: 8

Q1; Key Inflection Point: Voxelotor Full Phase 3 Data at EHA in June

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 226

05/09/2019

Company Report

Pages: 10

EHA Update, Rolling NDA Submission, and Commercial Readiness all During 2H19

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 227

05/06/2019

Daily Note

Pages: 10

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 228

04/29/2019

Company Report

Pages: 9

Price: 24.95

Industry: Medical - Biomedical and Genetics

Record: 229

04/18/2019

Company Report

Pages: 9

Hurdles for Sickle Cell Treatments and Anticipates Voxelotor Approval

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 230

04/12/2019

Daily Note

Pages: 11

With Voxelotor Motoring Along to Its 2H19 NDA Submission, a Quick Look at Inclacumab, the More Potent of the P-Selectins

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 231

03/28/2019

Company Report

Pages: 7

Price: 24.95

Industry: Medical - Biomedical and Genetics

Record: 232

03/05/2019

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 233

03/04/2019

Company Report

Pages: 9

Q4/FY18 Financials; Full Phase 3 HOPE Data Anticipated at EHA

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 234

02/28/2019

Company Report

Pages: 10

Rolling Submission for Voxelotor, In Line With our Expectation for This Best-in-Class Disease Modifying Therapy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 235

02/04/2019

Company Report

Pages: 8

Time to Buy: Plenty of Cash, Key Catalysts - Reduced Risk

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 236

02/04/2019

Company Report

Pages: 10

Checkin For Crizanlizumab and Checkout With Voxelotor

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 237

12/04/2018

Company Report

Pages: 14

Sitting Pretty for Voxelotor Approval and Plenty of Upside in Our View

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 238

12/03/2018

Company Report

Pages: 10

Regulatory Guidance Potentially Reflects Best Case Scenario; Target to $150

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 239

11/30/2018

Industry Report

Pages: 6

Correction: The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 240

11/28/2018

Company Report

Pages: 10

The Dichotomy Between Pain and VOC vs. End Organ Damage; Hence, AA May Not Be as Far Fetched

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party
// eof